Results 81 to 90 of about 223,054 (350)

P53‐dependent induction of ferroptosis is required for artemether to alleviate carbon tetrachloride‐induced liver fibrosis and hepatic stellate cell activation

IUBMB Life - A Journal of the International Union of Biochemistry and Molecular Biology, 2018
Ferroptosis is recently reported as a new mode of regulated cell death. Its essential characteristics are disturbed redox homeostasis, overloaded iron, and increased lipid peroxidation.
Ling-chong Wang, Zili Zhang, Mengmeng Li, Feixia Wang, Yan Jia, Feng Zhang, Jiangjuan Shao, Anping Chen, Shizhong Zheng   +8 more
semanticscholar   +1 more source

The miRNAome of the postpartum dairy cow liver in negative energy balance [PDF]

, 2014
peer-reviewedBackground: Negative energy balance (NEB) is an altered metabolic state in high yielding cows that occurs during the first few weeks postpartum when energy demands for lactation and maintenance exceed the energy supply from dietary ...
Fatima, Attia, Lynn, David J, Morris, Dermot G., O'Boyle, Padraic, Seoighe, Cathal   +4 more
core   +2 more sources

Bioengineered 3D hPSC‐Cholangiocyte Ducts With Physiological Signals for Biliary Disease Modeling

Advanced Healthcare Materials, EarlyView.
Tian and colleagues generated a bioengineered bile duct from human pluripotent stem cell (hPSC)‐derived intrahepatic cholangiocytes within a high‐throughput, 384‐well platform to systematically examine the influence of biliary physiological signals including fluid flow, stromal cells and bile acids, and models intrahepatic biliary disease progression ...
Britney Tian, Mina Ogawa, Manami Kondo, Gabrielle Langeveld, Ling Jun Huan, Feng Zhang, Andrew Hollinger, Sara Deir, Christine Bear, Boyang Zhang, Shinichiro Ogawa   +10 more
wiley   +1 more source

Differential Lipotoxic Effects of Palmitate and Oleate in Activated Human Hepatic Stellate Cells and Epithelial Hepatoma Cells

Cellular Physiology and Biochemistry, 2016
Background/Aims: Nonalcoholic fatty liver disease (NAFLD) progression to fibrosis, cirrhosis and hepatocellular carcinoma, alters the cellular composition of this organ.
Alexandra M. Hetherington, Cynthia G. Sawyez, Emma Zilberman, Alexandra M. Stoianov, Debra L. Robson, Nica M. Borradaile   +5 more
doaj   +1 more source

Epigenetic cell fate regulation of hepatic stellate cells [PDF]

Hepatology Research, 2011
Research in the past three decades has identified key mediators and signaling mechanisms responsible for myofibroblastic transdifferentiation (MTD) of hepatic stellate cells (HSC), the pivotal event in liver fibrogenesis. Yet, fundamental understanding of the MTD from the viewpoint of cell fate or lineage regulation has been elusive.
Hidekazu, Tsukamoto, Nian-Ling, Zhu, Kinji, Asahina, Derek A, Mann, Jelena, Mann   +4 more
openaire   +2 more sources

Essential Role of Lyn in Fibrosis. [PDF]

, 2016
Fibrotic disorders involve replacement of normal parenchyma with myofibroblasts, which deposit connective tissue, leading to obliteration of the function of the underlying organ.
Birtolo, Chiara, Chheda, Chintan, Cirulli, Vincenzo, Gugliotta, Gabriele, Lewis, Michael S, Liu, Sandy T, Pandol, Stephen J, Pham, Hung, Ptasznik, Andrzej, Rodriguez, Maria D, Yang, Wendy   +10 more
core   +2 more sources

Nanotherapies for Atherosclerosis: Targeting, Catalysis, and Energy Transduction

Advanced Healthcare Materials, EarlyView.
Atherosclerosis management is hindered by poor drug targeting and plaque heterogeneity. Nanotechnology overcomes these barriers via three core strategies: (1) target‐engineered nanocarriers that achieve lesion‐specific precision via ligand modification, biomimetic camouflage, stimuli‐responsive release, and self‐propelling nanomotors; (2) catalytic ...
Yuqi Yang, Jingguo Qu, Tonghuan Xiao, Xinyang Han, Michael Tin‐Cheung Ying   +4 more
wiley   +1 more source

Mechanism of acacetin regulating hepatic stellate cell apoptosis based on network pharmacology and experimental verification

Heliyon
Background: Hepatic fibrosis is caused by various liver diseases and eventually develops into liver cancer. There is no specific drug approved for the treatment of hepatic fibrosis in the world.
Xue Hu, Haotian Shen, Rong Liu, Bin Tang, Fengmei Deng   +4 more
doaj   +1 more source

Didymin Alleviates Hepatic Fibrosis Through Inhibiting ERK and PI3K/Akt Pathways via Regulation of Raf Kinase Inhibitor Protein

Cellular Physiology and Biochemistry, 2016
Background: Didymin has been reported to have anti-cancer potential. However, the effect of didymin on liver fibrosis remains illdefined. Methods: Hepatic fibrosis was induced by CCl4 in rats.
Xing Lin, Faicheng Bai, Jinlan Nie, Shengjuan Lu, Chunyuang Lu, Xunshuai Zhu, Jinbin Wei, Zhongpeng Lu, Quanfang Huang   +8 more
doaj   +1 more source

SIRT6 Protects Against Liver Fibrosis by Deacetylation and Suppression of SMAD3 in Hepatic Stellate CellsSummary

Cellular and Molecular Gastroenterology and Hepatology, 2020
Background & Aims: Nonalcoholic steatohepatitis (NASH) is a chronic liver disease that is manifested clinically by an increase in hepatic triglycerides, inflammation, and fibrosis. The pathogenesis of NASH remains incompletely understood.
Xiaolin Zhong, Menghao Huang, Hyeong-Geug Kim, Yang Zhang, Kushan Chowdhury, Wenjie Cai, Romil Saxena, Robert F. Schwabe, Suthat Liangpunsakul, X. Charlie Dong   +9 more
doaj   +1 more source